Technology transfer / Localization · MENA · Announced 15 Nov 2025
Bayer → Minapharm Pharmaceuticals
Bayer and Minapharm signed a cooperation agreement, witnessed by the Egyptian Drug Authority, to localize pharmaceutical manufacturing in Egypt with a focus on women's and reproductive health and family planning.
Parties: Bayer (Germany) → Minapharm Pharmaceuticals (Egypt)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Egypt, with export to regional and African markets
- Therapeutic area
- Women's Health
- Asset
- Women's health and family planning portfolio (products not named)
- Announced
- 15 Nov 2025
Our analysis
Why this matters
Minapharm Pharmaceuticals and Bayer signed a cooperation agreement on 15 November 2025 to localize pharmaceutical manufacturing in Egypt. The signing took place in the New Administrative Capital under the auspices of Deputy Prime Minister and Minister of Health and Population Khaled Abdel Ghaffar, alongside the Global Conference on Population, Health and Development, and was witnessed by the Egyptian Drug Authority (EDA). The EDA chairman described it as a step towards localizing the industry and transferring advanced technologies. Products, value and timelines were not disclosed.
The focus is women's health, reproductive health and family planning, tied to the Presidential Initiative for Egyptian Women's Health and Egypt's National Strategy for Population and Development 2023–2030. Egypt is positioned as a hub for regional and African export.
The full analysis is free to read with a work email on this page.
Source: Egyptian Drug Authority